Lupin launches Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets
This launch follows the receipt of approval for its ANDA from the USFDA
Lupin has launched Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, 10 mg/1,000 mg in the United States following the approval for its Abbreviated New Drug Application from the USFDA as bioequivalent to Xigduo XR for the indications in the approved labeling.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
